Fig. 2: Effects of CP55940 Co-administered with the CB1 inverse agonist AM251 on locomotion and fecal output in young–adult (4 m) and old (22 m) male C57BL/6 mice.

Varying doses of CP55940 were administered alone or in a pre-mixed solution with 3 mg/kg of AM251 to young–adult and old male mice. a, c Total distance moved (a) and total fecal output (c) by young–adult (4 m) mice during 30 m of open-field testing. b, d Total distance moved by old (22 m) mice during 30 m of open-field testing. All data have been normalized to the responses of vehicle-treated age-matched control animals which were tested at the same time. Individual data points for each testing group are overlaid on Tukey-style boxplots. The lower and upper edges of each box represent the first and third quartiles, respectively. The middle horizontal line in each box depicts the median of that dose/age group. Sample sizes for every treatment group and figure panel are listed in Supplementary Fig. 5. Significant omnibus results were followed by planned post hoc contrasts of each dose vs. vehicle-treated control groups using Dunn’s method. The false discovery rate was corrected for using the Benjamini, Hochberg, and Yekutieli method. Within an age group, significant differences (P < 0.05) between a given dose and the vehicle-treated response (0 dose) are indicated using asterisks (*). Differences between CP55940 alone and CP55940 + AM251 at a given dose are indicated by pound signs (#).